Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab Combinations in R/R NHL and Untreated DLBCL
NCT03467373Phase 1Completed
- Sponsor
- Roche
- Start
- Mar 2018
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 1, open-label trial of glofitamab in non-Hodgkin lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by Roche. Primary endpoints: Percentage of Participants with Dose Limiting Toxicities up to 29 months and Percentage of Participants with Adverse Events up to 29 months. Started Mar 2018; status: completed.
02
Drugs
glofitamab
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03467373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03467373.